Back to search results

Understanding Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening

This study wants to learn what patients like and dislike about screening tests for esophageal cancer (EAC) and Barrett's esophagus (BE), a condition that can lead to cancer. You would complete a survey to share your thoughts on different aspects of screening tests, such as how well they detect problems, how convenient they are, any discomfort they might cause, and their cost. The goal is to use this information to improve screening practices in the United States and help reduce deaths from esophageal cancer. This is an observational study, meaning you won't receive any medical treatments. The study plans to enroll 556 participants. To join, you should be between 18 and 89 years old and have at least three risk factors for BE, such as being over 50, having chronic GERD (Gastroesophageal Reflux Disease), or a family history of BE/EAC.

Study design
This is an observational study that plans to include 556 participants. It uses a survey to understand patient preferences for screening tests.
What's involved
You would complete a patient survey to share your preferences and barriers regarding different screening test attributes.
Compensation
Not stated in the trial record.
Follow-up
Patient preferences and barriers are measured at Baseline, so there is no specified follow-up period after this.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06693622

Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests

Recruiting
Not specifiedAges 18–89Observational
University of Colorado, Denver
~556 participants
Updated 2024-11-18 on ClinicalTrials.gov
What's tested:Patient survey

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Define patient preferred BE/EAC screening test and barriers for attributes of BE/EAC screening tests
Measured over Baseline

Conditions

Gastro Esophageal Reflux Disease
Barrett Esophagus

Explore related trials

Barrett EsophagusGastroesophageal Reflux Disease

Where it's being run

1 sites across 1 states
Colorado1

Study leadership

  • Sachin Wani, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
  • Jennifer Kolb, MD, MS · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

Alexa DeBord, MS
[email protected]
303-724-0432
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision to sign and date the consent form.
Stated willingness to comply with all study procedures and be available for the duration of the study.
Individual has 3 or more established risk factors for BE (age \> 50 years, chronic GERD, male, white race, smoking, obesity, family history of BE/EAC).

Exclusion

Unable to consent.
Prior diagnosis of BE/EAC.
Life limiting comorbidity/ disability.
Active dementia/ cognitive impairment.
Incarcerated.

What this trial measures

  • Define patient preferred BE/EAC screening test and barriers for attributes of BE/EAC screening testsBaseline

    A discrete choice-based conjoint analysis survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms will be used to determine the relative importance of BE/EAC screening test characteristics and patient priorities. Survey data will be reported in aggregate and factors and choices will be analyzed using the Fisher Exact and Mann-Whitney rank-sum tests. This approach will elicit the overall preferred test and differences in each test attribute that informed the patients choice.